High-Flow Nasal Therapy Trial for COPD Walking

Introduction

For patients with chronic obstructive pulmonary disease (COPD), simple walking can feel like a marathon. A planned pilot trial from Nagasaki University Hospital will test whether a portable device delivering high-flow air through the nose can safely help these individuals walk farther and breathe easier, using room air instead of supplemental oxygen.

Testing a Portable Device to Walk Farther

Led by Dr. Chikako Fukushima and colleagues, the trial will enroll twenty patients with moderate to severe COPD. Each participant will perform two six-minute walk tests in a single visit at Nagasaki University Hospital. In a randomized order, one walk will be done while using the AIRVO3™ portable nasal high-flow device, and the other will be a standard walk without the device. The primary measure is straightforward: how many more meters can a patient walk in six minutes while using the device? Secondary measures provide a deeper look at the physiological state, including continuous monitoring of skin oxygen saturation, respiratory rate, and a novel metric: transcutaneous partial pressure of carbon dioxide (PtcCO2). This non-invasive method estimates the amount of CO2 in the blood just beneath the skin, offering a window into how well the body is clearing this metabolic waste product during exertion.

The study is specifically designed to evaluate the pure effects of high airflow. The device will use room air with an inspiratory oxygen fraction of 21%—the same concentration we all breathe. “By using room air and focusing on high flow rather than high oxygen concentration,” the authors write, “this study will clarify the pure effects of high-flow nasal therapy on exertional capacity.” This separates the potential benefits of airflow mechanics from those of increased oxygen delivery, a distinction important for understanding the underlying mechanism.

How High-Flow Air Alleviates the Breathless Burden of COPD

The rationale for this approach is grounded in the specific breathing challenges of COPD. The disease causes airflow limitation and air trapping, which increases the work of breathing and leaves stale air rich in CO2 in the lungs’ anatomical dead space—the airways that don’t participate in gas exchange. Nasal high-flow therapy addresses this in several direct ways.

First, the high flow rate of warmed, humidified air physically flushes out this CO2-rich dead space with fresh air. This “washout” effect means each new breath starts with a lower concentration of CO2 in the upper airways, creating a more favorable gradient for CO2 to exit the blood. Second, the flow generates a small, variable amount of positive pressure in the upper airway, which can help stent open floppy airways and reduce the effort needed to inhale. Third, adequate humidification improves the function of the cilia, the tiny hair-like structures that move mucus, potentially aiding clearance. Together, these actions aim to make breathing more efficient, slowing the rapid, shallow breathing pattern that leads to exhaustion. The researchers will track this by measuring the time it takes for a patient’s respiratory rate to exceed 22 breaths per minute during the walk test.

Central to this trial is the focus on CO2 management. Patients with severe COPD often struggle to exhale CO2 adequately, leading to retention and elevated blood levels (hypercapnia). This build-up is a direct trigger for the distressing sensation of dyspnea, or air hunger. By monitoring PtcCO2, the team can see if the high-flow therapy effectively delays or prevents this rise during exercise. A related article on our site, CO2 Fear: Brain Inflammation Causes Hyperventilation, explores how the brain’s sensitivity to CO2 drives breathing behavior, highlighting why managing CO2 levels is so critical for respiratory comfort.

Potential Applications Beyond a Single Walk Test

Should the AIRVO3™ prove safe and effective in this acute setting, the implications extend beyond a laboratory walking test. The most immediate application would be within pulmonary rehabilitation programs. These structured exercise and education courses are a standard of care for COPD but are often limited by patients’ rapid onset of breathlessness. Integrating portable high-flow therapy could allow participants to exercise at a higher intensity or for longer durations, potentially leading to greater gains in cardiovascular fitness and muscle strength.

Furthermore, a device deemed acceptable for ambulation opens the door to supporting physical activity in daily life. Patients might use it during walks outdoors, gardening, or performing household chores—activities they may have abandoned due to dyspnea. This aligns with the goal of modern COPD management, which emphasizes maintaining an active lifestyle to preserve quality of life. As explored in our article on Digital Tools and Training to Reduce COPD Exacerbations, combining technological aids with behavioral strategies represents a multi-faceted approach to disease management.

It is important to note the study’s limitations as a pilot trial. With only twenty participants, it is designed to assess feasibility, safety, and signal of effectiveness, not to provide definitive proof. The single-center, open-label design (where both patients and researchers know which treatment is being used) introduces potential for bias, though the randomized crossover structure helps control for individual variation. The outcomes are also acute, measured within a single day, leaving the longer-term adherence and benefits an open question.

Conclusion

The Nagasaki trial represents a focused investigation into whether a simple mechanical intervention—high-flow normal air—can recalibrate the inefficient breathing mechanics of COPD. By targeting CO2 washout and breathing work, it offers a non-pharmacological path to better exercise tolerance. Success could provide a new, practical tool to help patients move more freely.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41816455/
https://pubmed.ncbi.nlm.nih.gov/39935352/
https://pubmed.ncbi.nlm.nih.gov/39879158/